Moderna Inc. Receives US Approval for RSV Vaccine in Older Adults

Moderna Inc. has recently received approval from the US Food and Drug Administration for its RSV vaccine in older adults, marking a significant milestone for the biotech company. This approval grants Moderna a second product in its portfolio as it looks to diversify beyond its Covid-19 vaccine offerings.

The RSV vaccine, known as mRESVIA, is targeted towards adults aged 60 and older and is designed to combat respiratory syncytial virus, a flu-like illness that particularly impacts elderly adults and babies. This approval comes after a delay due to administrative constraints at the FDA, but Moderna is now gearing up to make mRESVIA available in the US for the upcoming fall respiratory virus season.

The approval of the RSV vaccine is a crucial development for Moderna, which has been seeking to expand its product offerings beyond its Covid-19 shot. With the pandemic waning and demand for Covid vaccines decreasing, the RSV vaccine provides Moderna with a new revenue stream and showcases its capabilities in mRNA technology for diseases beyond Covid.

Despite facing a slight decline in effectiveness during FDA analysis, Moderna’s RSV vaccine is poised to compete with existing products from GSK and Pfizer in the market. Moderna’s unique advantage lies in the convenience of its pre-filled syringe, making it easier for pharmacists to administer compared to other options.

Looking ahead, the RSV market for seniors is projected to be worth $11 billion by 2032, with Moderna aiming to capture a significant share alongside GSK and Pfizer. As advisers to the US Centers for Disease Control and Prevention convene to discuss recommendations for this year’s RSV shots, Moderna’s approval signals a new chapter in the company’s growth and innovation in the biotech industry.